Multiple shape memory behavior of highly oriented long‐chain‐branched poly(lactic acid) and its recovery mechanism

YesThe shape memory effect of highly oriented long‐chain‐branched poly(lactic acid) (LCB‐PLA) prepared through solid‐phase die drawing technology was studied by comparison with PLA. When the recovery temperature increased from 60°C to 120°C, for PLA, only one‐step recovery at about 80°C can be observed and the recovery ratio was below 21.5%, while, for LCB‐PLA, multiple recovery behavior with high recovery ratio of 78.8% can be achieved. For oriented PLA, the recovery curve of the final sample showed the same trend with that of sample suffering just free drawing; while for oriented LCB‐PLA, the recovery curve of the final sample showed the same trend with that of sample suffering just die drawing. After shape recovery, the mechanical properties of LCB‐PLA showed a linear downward trend with the recovery temperature. Together with amorphous phase, the oriented mesomorphic phase, which formed during solid die drawing, can act as switching domains. And thus, upon heating, the chain segment of amorphous phase relaxed at first and triggered the first macroscopical shape recovery, leading to the decrease of long period (Lac) and the thickness of the amorphous layer (La). Then, with further increasing temperature, the oriented mesomorphic phase gradually relaxed resulting subsequently multi‐shape recovery, and the Lac and the La further decreased. Therefore, by regulating the recovery temperature of oriented LCB‐PLA, the shape recovery ratio and mechanical strength can be controlled effectively, and thus the self‐reinforced and self‐fastening effect can be achieved simultaneously for PLA as bone fixation material

Structure and blood compatibility of highly oriented poly(l-lactic acid) chain extended by ethylene glycol diglycidyl ether

YesHighly-oriented poly(l-lactic acid) (PLLA) with fibrillar structure and micro-grooves was fabricated through solid hot drawing technology for further improving the mechanical properties and blood biocompatibility of PLLA as blood-contacting medical devices. In order to enhance the melt strength and thus obtain high orientation degree, PLLA was first chain extended with ethylene glycol diglycidyl ether (EGDE). The extending degree as high as 25.79 mol% can be obtained at 0.7 wt% EGDE content. The complex viscosity, storage and viscous modulus for chain extended PLLA were improved resulting from the enhancement of molecular entanglement, and consequently higher draw ratio can be achieved during the subsequent hot stretching. The tensile strength and modulus of PLLA were improved dramatically by stretching. The stress-induced crystallization of PLLA occurred during drawing. The interfacial tension (γs·blood) between PLLA surface and blood decreased by chain extension and molecular orientation, indicating the weakened interaction between bioactive substance in the blood and the surface of PLLA. Modification and orientation could significantly enhance the blood compatibility of PLLA by prolonging clotting time and decreasing hemolysis ratio, protein adsorption and platelet activation. The bionic character of oriented PLLA and its anti-coagulation mechanism were tried to be explored.This research was supported by National Natural Science Foundation of China (Grant No. 51303109

Structure and blood compatibility of highly oriented PLA/MWNTs composites produced by solid hot drawing

YesHighly oriented poly(lactic acid) (PLA)/multi-walled carbon nanotubes (MWNTs) composites were fabricated through solid hot drawing technology in an effort to improve the mechanical properties and blood biocompatibility of PLA as blood-contacting medical devices. It was found that proper MWNTs content and drawing orientation can improve the tensile strength and modulus of PLA dramatically. With the increase in draw ratio, the cold crystallization peak became smaller, and the glass transition and the melting peak of PLA moved to high temperature, while the crystallinity increased, and the grain size decreased, indicating the stress-induced crystallization of PLA during drawing. MWNTs showed a nucleation effect on PLA, leading to the rise in the melting temperature, increase in crystallinity and reduction of spherulite size for the composites. Moreover, the intensity of (002) diffraction of MWNTs increased with draw ratio, indicating that MWNTs were preferentially aligned and oriented during drawing. Microstructure observation demonstrated that PLA matrix had an ordered fibrillar bundle structure, and MWNTs in the composite tended to align parallel to the drawing direction. In addition, the dispersion of MWNTs in PLA was also improved by orientation. Introduction of MWNTs and drawing orientation could significantly enhance the blood compatibility of PLA by prolonging kinetic clotting time, reducing hemolysis ratio and platelet activation

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

Objectives: To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the association of MDA status with independent quality of life (QoL)-related patient-reported outcomes (PROs). Methods: Univariate and multivariate analyses were used to identify the baseline characteristics that predicted achievement of MDA at individual time points (weeks 12 through 144) or sustained MDA (achievement of MDA at 2 consecutive time points 12 weeks apart). The association of independent QoL-related PROs with MDA achievement was evaluated at weeks 24 and 144. Results: In univariate analyses, higher baseline patient assessment of pain, tender joint count (TJC), enthesitis and Health Assessment Questionnaire-Disability Index (HAQ-DI) score were significantly associated with lower likelihood of achieving MDA at later time points. Multivariate analyses confirmed higher baseline HAQ-DI as a significant predictor for failure to achieve MDA at later time points. Achievement of sustained MDA was associated with lower baseline TJC and HAQ-DI score. Achievement of different MDA components appeared to be treatment dependent. MDA achievers had significantly better QoL-related PROs and greater improvements in PROs from baseline to week 24 compared with non-achievers. Conclusions: Higher HAQ-DI score was the most consistent baseline factor that decreased the likelihood of achieving MDA and sustained MDA at later time points. Achieving MDA was associated with better independent QoL-related PROs

Enhancing poly(lactic acid) microcellular foams by formation of distinctive crystalline structures

YesBy controlling the crystallization behavior of poly(lactic acid) (PLA) in the presence of a hydrazide nucleating agent (HNA), PLA-HNA foams with enhanced microcellular structures were prepared via supercritical CO2 foaming. It was found that HNA can self-assemble into fibrillar networks, inducing the crystallization of PLA on their surface, and "shish-kebab"crystalline structures with high crystallinity formed, which can be maintained during the whole foaming process. Incorporation of HNA promoted the formation of gt conformers, improved the amount of dissolved CO2, hindered the escape of CO2, and increased the viscoelasticity of PLA. Compared with neat PLA foam, for PLA-HNA foam, the average cell diameter decreased obviously, from 64.39 to 6.59 μm, while the cell density increased up to nearly three orders of magnitudes, from 6.82 × 106 to 4.44 × 109 cells/cm3. Moreover, lots of fibrillar structures appeared and entangled with each other on the cell wall of the foam. By forming such dense micropores and enhanced fibrillar structures, PLA foam was highly reinforced with significantly improved compressive strength.This research was financially supported by National Natural Science Foundation of China (grant no. 51773122) and State Key Laboratory of Polymer Materials Engineering (grant no. sklpme2019-2-21)

In Situ Cross-Linking of Poly(vinyl alcohol)/Graphene Oxide–Polyethylene Glycol Nanocomposite Hydrogels as Artificial Cartilage Replacement: Intercalation Structure, Unconfined Compressive Behavior, and Biotribological Behaviors

YesPoly(vinyl alcohol) (PVA)/graphene oxide (GO) nanocomposite hydrogel as artificial cartilage replacement was prepared via freezing/thawing method by introducing polyethylene glycol (PEG). Efficient grafting of PVA molecules onto GO surface was realized by formation of hydrogen bonding, resulting in exfoliation and uniform distribution of GO in PVA matrix. By introduction of appropriate content of GO, the increased crystalline regions of PVA and the formation of GO centered second network structure led to the increase of the storage modulus and effective cross-linking density. And therefore the mechanical strength and toughness of the composite hydrogel were improved simultaneously: the tensile strength, elongation at break, and compressive modulus showed approximately 200%, 40%, and 100% increase of the neat PVA hydrogel. Besides, for the sample with 1.5 wt % GO content, the maximum force retention and dynamic stiffness were improved remarkably in the process of sinusoidal cyclic compression, and the compressive relaxation stress also increased significantly, indicating the enhancement of the compressive recoverable and antifatigue ability, and resistance to compressive relaxation by formation of high load-bearing, dense, and reinforcing double network structure. Moreover, more than 50% decrease in coefficient of friction was obtained for the composite hydrogel, and the worn surface presented relative smooth and flat features with sharp decreasing furrow depth, confirming the lubrication effect of GO-PEG. This study shows promising potentials in developing new materials for cartilage replacement with simultaneous combination of high mechanical property and excellent lubrication

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis

Introduction: This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). Methods: A total of 84 patients with oligoarticular PsA, defined as 1–4 tender joints and 1–4 swollen joints, were pooled from the FUTURE 2–5 and MAXIMISE trials (NCT01752634, NCT01989468, NCT02294227, NCT02404350, and NCT02721966). Patients were grouped by treatment received at week 12 (secukinumab 300 mg, secukinumab 150 mg, or placebo) and week 52 (any secukinumab 300 mg or any secukinumab 150 mg). Efficacy was assessed by the proportion of patients achieving selected clinical outcomes. The predictors of Disease Activity index for Psoriatic Arthritis (DAPSA) responses at weeks 12 and 52 were identified by logistic regression analysis. Results: Secukinumab treatment resulted in greater achievement of DAPSA-based low disease activity (LDA), DAPSA-based remission (REM), DAPSA50, and DAPSA75 than placebo at week 12, with improvements sustained or further increased through week 52. LDA or REM was achieved at week 52 by more than 90% of patients who received either secukinumab dose, although secukinumab 300 mg resulted in the highest achievement of the stringent DAPSA75 and DAPSA REM outcomes. At week 12, younger age was associated with DAPSA LDA or REM and DAPSA50, while lower baseline swollen joint count was associated with DAPSA REM. No predictors were identified at week 52. The safety profile was consistent with the full study populations. Conclusion: Secukinumab demonstrated efficacy vs placebo across several outcome measures in patients with oligoarticular PsA at week 12, with sustained or improved responses through week 52

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

Objective To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study. Methods FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA/DAPSA REM): not achieving LDA/REM, achieving it once or sustained LDA/REM ≥3 times up to week 104. Key outcomes were improvements in Health Assessment Questionnaire Disability Index and Short Form-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response. Results Patients were randomised (N=996) into the following treatment groups: secukinumab 300 mg (N=222), secukinumab 150 mg loading (N=220)/non-loading (N=222) and placebo (N=332). Baseline characteristics were comparable between patients with sustained DAPSA and MDA responses. By week 104, 48%–81% and 19%–36% of the secukinumab-treated patients achieved sustained LDA and REM, respectively. Numerically greater improvements in physical function and QoL were observed with sustained LDA/REM versus LDA/REM achieved once or not at all, although patients reached the established minimal clinically important difference for all composite indices. A high proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM. Younger age, lower body mass index at baseline, reduced tender joint count and PsA pain at week 16 were key predictors of sustained LDA in secukinumab-treated patients. Conclusion Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression

3D simulation of the Hierarchical Multi-Mode Molecular Stress Function constitutive model in an abrupt contraction flow

YesA recent development of the Molecular Stress Function constitutive model, the Hierarchical Multi-Mode Molecular Stress Function (HMMSF) model has been shown to fit a large range of rheometrical data with accuracy, for a large range of polymer melts. We develop a 3D simulation of the HMMSF model and compare it to experimental data for the flow of Lupolen 1840H LDPE through an abrupt 3D contraction flow. We believe this to be the first finite element implementation of the HMMSF model. It is shown that the model gives a striking agreement with experimental vortex opening angles, with very good agreement to full-field birefringence measurements, over a wide range of flow rates. A method to give fully-developed inlet boundary conditions is implemented (in place of using parabolic inlet boundary conditions), which gives a significantly improved match to birefringence measurements in the inlet area, and in low stress areas downstream from the inlet. Alternative constitutive model parameters are assessed following the principle that extensional rheometer data actually provides a ‘lower bound’ for peak extensional viscosity. It is shown that the model robustly maintains an accurate fit to vortex opening angle and full-field birefringence data, provided that both adjustable parameters are kept such that both shear and extensional data are well fitted